Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders

Author's Avatar
Jun 16, 2020
Article's Main Image

Neurocrine Biosciences, Inc. (Nasdaq%3ANBIX) and Takeda Pharmaceutical Company Limited (TSE%3A4502%2FNYSE%3ATAK) (“Takeda”) today announced a strategic collaboration to develop and commercialize compounds in Takeda’s early-to-mid-stage psychiatry pipeline. Specifically, Takeda granted an exclusive license to Neurocrine Biosciences for seven pipeline programs, including three clinical stage assets for schizophrenia, treatment-resistant depression and anhedonia.